TLS Beta Pte. Ltd. 3
3 · Vir Biotechnology, Inc. · Filed Oct 10, 2019
Insider Transaction Report
Form 3
TLS Beta Pte. Ltd.
10% Owner
Holdings
- (indirect: See footnote)
Series B Preferred Stock
→ Common Stock (1,666,666 underlying) - (indirect: See footnote)
Series A-1 Preferred Stock
→ Common Stock (3,333,333 underlying)
Footnotes (2)
- [F1]The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
- [F2]The securities reported herein are directly held by TLS Beta Pte. Ltd, which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.